247234-41-9

Basic information

• Product Name: N-[4-(Morpholin-4-yl)phenyl]guanidine
• Synonyms: 4-Morpholinophenylguanidine;N-[4-(Morpholin-4-yl)phenyl]guanidine;1-(4-Morpholinophenyl)guanidine;1-[4-(4-Morpholinyl)phenyl]guanidine, 98%
• CAS NO: 247234-41-9
• Molecular Formula: C₁₁H₁₆N₄O
• Molecular Weight: 220.274
• Mol File: 247234-41-9.mol
• Article Data: 9

Chemical Properties

• Melting Point: ca 220℃
• Boiling Point: 457.246 °C at 760 mmHg
• Flash Point: 230.334 °C
• Appearance: /
• Density: 1.30
• PKA: 11.95±0.10(Predicted)
• CAS DataBase Reference: N-[4-(Morpholin-4-yl)phenyl]guanidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(Morpholin-4-yl)phenyl]guanidine(247234-41-9)
• EPA Substance Registry System: N-[4-(Morpholin-4-yl)phenyl]guanidine(247234-41-9)

Safety Data

• Hazardous Substances Data: 247234-41-9(Hazardous Substances Data)

Usage

General Description

N-[4-(Morpholin-4-yl)phenyl]guanidine, also known as Morantel, is a chemical compound that belongs to the guanidine class of compounds. It is commonly used as an anthelmintic drug for the treatment of parasitic worm infestations in livestock, particularly in sheep and cattle. Morantel works by paralyzing the parasites, causing them to detach from the intestinal walls and be expelled from the body. It is considered to be a relatively safe and effective treatment for a variety of intestinal worms, including roundworms, hookworms, and whipworms. However, as with all chemical compounds, it is important to handle and use Morantel with caution and follow proper safety protocols to prevent any potential adverse effects on human health and the environment.

Upstream product

• 1027376-20-0 C₂₆H₂₅N₃O₃S 
• 2524-67-6 4-morpholino-4-yl-phenylamine 
• 420-04-2 CYANAMID 
• 100-00-5 4-chlorobenzonitrile 
• 10389-51-2 1-morpholino-4-nitrobenzene 

Downstream Products

• 1159883-57-4 C₂₅H₂₁N₇O₃S 
• 1159883-59-6 N-(3-(5-(2-((4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)imidazo[2,1-b][1,3]thiazol-6-yl)phenyl)benzamide 
• 1056634-68-4 Momelotinib 
• 945749-71-3 4-(2-(4-(morpholinophenyl)amino)pyrimidin-4-yl)benzoic acid 
• 1383074-06-3 4-(1-methyl-1H-benzimidazol-2-yl)-N-[4-(morpholin-4-yl)phenyl]pyrimidin-2-amine 

Relevant articles and documents

Synthesis of Imidazoles and Oxazoles via a Palladium-Catalyzed Decarboxylative Addition/Cyclization Reaction Sequence of Aromatic Carboxylic Acids with Functionalized Aliphatic Nitriles

We herein report an efficient approach for the assembly of multiply substituted imidazoles and oxazoles in a single-step manner. These transformations are based on a decarboxylation addition and annulation of readily accessible aromatic carboxylic acids a

Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors

CDK4/6 pathway is an attractive target for development of anti-cancer drugs. Herein, we reported the design and synthesis of a series of 4,5-dihydro-1H-pyrazolo [4,3-h]quinazoline derivatives as selective CDK4/6 inhibitors. Applied with the optimizing strategy to the initial scaffold, it is found that compound 13n is able to selectively inhibit CDK4 and CDK6 with IC50 values 0.01 and 0.026 μM, respectively. The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor. This compound was also found to have favorable pharmacokinetic parameters. Taken together, compound 13n could be selected for further preclinical evaluation.

A novel and efficient synthesis of momelotinib

An improved route for the synthesis of momelotinib has been developed. A nucleophilic addition reaction between the starting material, 4-morpholinoaniline, and cyanamide gave the 1-(4-morpholinophenyl)guanidine. Simultaneously, methyl 4-acetylbenzoate was converted into methyl (E)-4-[3-(dimethylamino)acryloyl]benzoate in the presence of N,N-dimethylformamide dimethylacetal. The enaminone intermediate was then condensed at elevated temperature in alcoholic alkali with the 1-(morpholinophenyl)guanidine to form the desired pyrimidine, which was hydrolysed to the corresponding acid. This procedure is simple in operation, without noble metal catalyst and suitable for industrial production. Finally, the desired compound momelotinib was acquired by an amidation reaction.